

Pemazyre (pemigatinib)
Effective 01/01/2021

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Pemigatinib is a fibroblast growth factor receptor (FGFR) inhibitor used to treat unresectable, locally advanced or metastatic cholangiocarcinoma.

Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with Pemazyre, excluding when the product is obtained as samples or via manufacturer's patient assistance program

OR

Authorization may be granted if the member meets all the following criteria and documentation has been submitted:

1. The member is diagnosed with unresectable, locally advanced or metastatic cholangiocarcinoma
2. The tumor has FGFR2 fusion or other rearrangement
3. The member is at least 18 years of age
4. The member has received at least one prior treatment
5. The prescriber is an oncologist or medication is being prescribed in consultation with an oncologist.

Limitations

1. Initial approvals and reauthorizations will be granted for 12 months
2. The following quantity limits apply:

Pemazyre	21 tablets per 30 days
----------	------------------------

References

1. Pemazyre (pemigatinib) [prescribing information]. Wilmington, DE: Incyte Corporation; April 2020.
2. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [published online March 20, 2020]. *Lancet Oncol*. doi:10.1016/S1470-2045(20)30109-1

Review History

11/18/2020- Reviewed at Nov P&T Mtg.

